A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with aids

Clinical Infectious Diseases

Volumn 26, Issue 6, 1998, Pages 1368-1373

  Phillips, Peter ^a   De Beule, Karel ^b   Frechette, Gervais ^b   Tchamouroff, Stephan ^b   Vandercam, Bernard ^b   Weitner, Lutwinus ^b   Hoepelman, Andy ^b   Stingl, Georg ^b   Clotet, Buenaventura ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FLUCONAZOLE; ITRACONAZOLE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OROPHARYNX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; TREATMENT OUTCOME;

EID: 0031863780     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516342     Document Type: Article

References (24)

1. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;311:354-8.
2. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991;5:519-25.
3. Bennett JE. Antifungal agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilmon AG, eds. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1175-90.
4. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50:658-90.
5. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990;21:55-60.
6. Marriott DJE, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients: a double-blind placebo-controlled study. Med J Aust 1993;158:312-6.
7. Kitchen VS, Savage M, Harris JRW. Candida albicans resistance in AIDS [letter]. J Infect 1991;22:204-5.
8. Heinic GS, Stevens DA, Greenspan D, et al. Fluconazole-resistant Candida in AIDS patients: report of two cases. Oral Surg Oral Med Oral Pathol 1993;76:711-5.
9. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-92.
10. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-2.
11. Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS - a therapeutic approach. J Infect 1993;26:117-25.
12. Phillips P. Resistant oropharyngeal candidiasis in AIDS. Bailliéres Clin Infect Dis 1996;3:49-62.
13. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991;5:1367-71.
14. de Repentigny L, Ratelle J, Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Chemotherapy 1996;42:374-83.
15. Hoepelman IM, Dupont B. Oral candidiasis: the clinical challenge of resistance and management. Int J Antimicrob Agents 1996;6:155-9.
16. Desmet P, Kayembe K, Stoffels P, Mulumba MP, De Beule K, Cauwenbergh G. Treatment of oral candidosis in AIDS patients with itraconazole oral solution [abstract no P35]. In: Proceedings and abstracts of the Third Symposium on Topics in Mycology. Paris: International Society for Human and Animal Mycology and the Pasteur Institute, 1989.
17. Blackwelder W. 'Proving the null hypothesis' in clinical trials. Controlled Clin Trials 1982;3:345-53.
18. Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104:33-9.
19. + patients [abstract no 2131]. Can J Infect Dis 1995;6 (suppl C).
20. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1530-3.
21. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;32:2092-8.
22. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution - effective treatment for HIV-related candidosis unresponsive to other azole therapy [letter]. J Antimicrob Chemother 1994;33:1071-3.
23. Gänger G, Just-Nübling G, Eichel M, Hoika R, Stille JW. Itraconazole solution in patients with non-response to fluconazole. In: Program and abstracts of the 9th International Conference on AIDS (Berlin). Berlin: Institute for Clinical and Experimental Virology of the Free University of Berlin, 1993.
24. Phillips P, Zemcov J, Mahmood W, Montaner J, Craib K, Clarke A. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidosis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996;10:1369-76.